LGM
VRTX icon

Logos Global Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Logos Global Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-33,237
Closed -$7.91M – 64
2020
Q1 		$7.91M Buy
+33,237
New +$7.62M 3.01% 12

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Logos Global Management's VRTX Position: Q2 2020 in Review

Logos Global Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2020, closing a stake of 33,237 shares — an estimated $7.91M sold.

Logos Global Management first reported a position in VRTX in Q1 2020 and held it in 1 quarter. The position peaked at $7.91M in Q1 2020. 963 funds tracked by Wall St. Rank hold VRTX as of Q2 2020.

  • Logos Global Management reported no remaining Vertex Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Logos Global Management sold 33,237 Vertex Pharmaceuticals shares in Q2 2020, an estimated $7.91M.
  • Logos Global Management first reported a position in Vertex Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Logos Global Management's Vertex Pharmaceuticals position peaked at $7.91M in Q1 2020.
  • 963 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2020.

Based on Logos Global Management's 13F filing for Q2 2020, filed 14 Aug 2020.